In SCLC, combining PARP inhibition with radiotherapy elevates the levels of chemokines such as CCL5 and CXCL10, effectively turning an “immune desert” tumor into an “immune-enriched” tumor that is more receptive to PD-1/PD-L1 blockade [88–90]. This evidence concerns the gene PDCD1 and neoplasm.